-
141
Interventions to increase utilisation of advanced care planning documentation for hospitalised older adults
Published 2025-01-01Get full text
Article -
142
Effect of Ionizers on Indoor Air Quality and Performance of Air Cleaning Systems
Published 2023-12-01Get full text
Article -
143
Immunogenetics of longevity and its association with human endogenous retrovirus K
Published 2025-02-01Get full text
Article -
144
-
145
An Examination of the Role of Transcriptional and Posttranscriptional Regulation in Rhabdomyosarcoma
Published 2017-01-01Get full text
Article -
146
Building a Partnership World: Imagining a Future of Cooperation and Equity
Published 2024-12-01Get full text
Article -
147
Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy
Published 2020-01-01Get full text
Article -
148
-
149
A New Method to Measure Crack Extension in Nuclear Graphite Based on Digital Image Correlation
Published 2017-01-01Get full text
Article -
150
-
151
Thyroglossal Duct Cyst Carcinoma in a Young Female: Case Report and Review of Literature
Published 2019-01-01Get full text
Article -
152
-
153
-
154
Patients’ Perceptions of their Participation in a Clinical Trial for Postoperative Crohn’s Disease
Published 1998-01-01Get full text
Article -
155
-
156
Distances to emergency departments and non-urgent utilization of medical services: a systematic review
Published 2024-12-01Get full text
Article -
157
-
158
-
159
-
160
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
Published 2025-01-01“…Separately, we evaluated overall RFS (composite of time to clinical relapse, ADAMTS13 relapse, or preemptive rituximab) in a prospective iTTP cohort from the Johns Hopkins University and the University of Minnesota. In the USTMA registry, median clinical RFS was shorter after the second or subsequent rituximab-treated episode than the first (2.1 vs 6.0 years; P = .04). …”
Get full text
Article